Evidence map›Paper›PMID 26098778›Full record

ArticleOncotarget2015

Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.

Saroj K Basak, Alborz Zinabadi, Arthur W Wu, Natarajan Venkatesan, Victor M Duarte, James J Kang, Clifton L Dalgard, Meera Srivastava, Fazlul H Sarkar, Marilene B Wang and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. HPVTranslational oncology · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Saroj K BasakDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Alborz ZinabadiDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Arthur W WuDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Natarajan VenkatesanDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Victor M DuarteDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
James J KangDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Clifton L DalgardDepartments of Anatomy, Physiology and Genetics, Molecular and Cell Biology, Uniformed Services University, Bethesda, MD, USA.
Meera SrivastavaDepartments of Anatomy, Physiology and Genetics, Molecular and Cell Biology, Uniformed Services University, Bethesda, MD, USA.
Fazlul H SarkarKarmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Marilene B WangDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Eri S SrivatsanDepartment of Surgery, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
VA Greater Los Angeles Healthcare System · USUniversity of California, Los Angeles · USUniformed Services University of the Health Sciences · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer, with 600,000 new cases every year worldwide. Although chemotherapeutics exist, five-year survival is only 50%. New strategies to overcome drug resistance are required to improve HNSCC treatment. Curcumin-difluorinated (CDF), a synthetic analog of curcumin, was packaged in liposomes and used to evaluate growth inhibition of cisplatin resistant HNSCC cell lines CCL-23R and UM-SCC-1R generated from the parental cell lines CCL-23 and UM-SCC-1 respectively. Growth inhibition in vitro and expression levels of the CD44 (cancer stem cell marker), cytokines, and growth factors were investigated after liposomal CDF treatment. The in vivo growth inhibitory effect of liposomal CDF was evaluated in the nude mice xenograft tumor model of UM-SCC-1R and the inhibition of CD44 was measured. Treatment of the resistant cell lines in vitro with liposomal CDF resulted in a statistically significant growth inhibition (p < 0.05). The nude mice xenograft study showed a statistically significant tumor growth inhibition of UM-SCC-1R cells and a reduction in the expression of CD44 (p < 0.05), indicating an inhibitory effect of liposomal CDF on CSCs. Our results demonstrate that delivery of CDF through liposomes may be an effective method for the treatment of cisplatin resistant HNSCC.

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, Squamous CellCell Line, TumorCell ProliferationCisplatinCurcuminCytokinesDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansHyaluronan ReceptorsHydrocarbons, FluorinatedLiposomesAntineoplastic AgentsCisplatinCurcuminCytokinesHyaluronan ReceptorsHydrocarbons, FluorinatedLiposomescancer stem cell (CSC)cisplatincurcumin-difluorinated (CDF)drug resistancehead and neck cancer

Identifiers

PMID26098778
PMCPMC4621906
OpenAlexW1515182641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.